Hologic (NASDAQ:HOLX) was upgraded by equities researchers at Cowen from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Monday, The Fly reports.

A number of other research firms also recently commented on HOLX. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 price target on shares of Hologic in a research note on Monday, October 2nd. Piper Jaffray Companies restated a “buy” rating and issued a $48.00 target price on shares of Hologic in a research note on Thursday, November 9th. Royal Bank Of Canada restated a “hold” rating and issued a $42.00 target price on shares of Hologic in a research note on Friday, September 22nd. Jefferies Group restated a “buy” rating and issued a $44.00 target price (down from $49.00) on shares of Hologic in a research note on Tuesday, October 10th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $45.00 target price (down from $48.00) on shares of Hologic in a research note on Monday, October 9th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $47.62.

Hologic (NASDAQ HOLX) opened at $42.69 on Monday. The company has a market capitalization of $11,768.93, a PE ratio of 21.13, a P/E/G ratio of 2.06 and a beta of 0.95. Hologic has a 52 week low of $35.76 and a 52 week high of $46.80. The company has a quick ratio of 0.61, a current ratio of 0.79 and a debt-to-equity ratio of 0.79.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. The business had revenue of $802.90 million during the quarter, compared to the consensus estimate of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period last year, the firm earned $0.52 earnings per share. analysts anticipate that Hologic will post 2.12 EPS for the current fiscal year.

In other news, Director Lawrence M. Levy sold 9,596 shares of Hologic stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total transaction of $353,228.76. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Elaine Ullian sold 9,282 shares of Hologic stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $40.50, for a total value of $375,921.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,833 shares of company stock valued at $1,107,270. 0.79% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Grove Bank & Trust raised its holdings in shares of Hologic by 115.8% during the third quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after buying an additional 1,535 shares during the last quarter. Hall Laurie J Trustee raised its holdings in shares of Hologic by 10.2% during the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after buying an additional 225 shares during the last quarter. Commonwealth Bank of Australia raised its holdings in Hologic by 31.0% during the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after purchasing an additional 600 shares in the last quarter. MPS Loria Financial Planners LLC bought a new stake in Hologic during the second quarter worth approximately $191,000. Finally, National Asset Management Inc. bought a new stake in Hologic during the second quarter worth approximately $203,000. 98.08% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/12/11/hologic-holx-stock-rating-upgraded-by-cowen.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

The Fly

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.